Conference Learning Objectives

JADPRO Live Virtual 2020 is designed to help advanced practitioners meet the following overarching objectives:

• Evaluate treatment paradigms for select solid tumors and hematologic malignancies, based on guidelines and best practices.
• Interpret the potential clinical significance of emerging data relevant to safe and effective cancer treatment.
• Anticipate and mitigate adverse events (AEs) associated with cancer treatments.
• Develop collaborative strategies to enhance communication with, and the quality of life of, individuals undergoing cancer treatment.

Below are the learning objectives for individual sessions.

A Multidisciplinary Approach to Head and Neck Cancer

• List the various types of head and neck cancers, associated treatments, and side-effect management
• Describe the role of de-escalation treatment in the management of head and neck cancer
• Discuss the role of the advanced practice provider in survivorship of head and neck cancer
• Describe the prevalence of HPV infection and the role of HPV vaccination in the prevention of head and neck cancer

Advanced Prostate Cancer: Considerations for Advanced Practitioners

• Define advanced prostate cancer
• Identify treatment options for hormone-sensitive metastatic prostate cancer, as well as nonmetastatic and metastatic castration-resistant disease
• Explain the role of genetics and genomic testing in patients with advanced prostate cancer

Approaches to Treating the Hospitalized Patient With Thrombocytopenia

• Recognize common causes of thrombocytopenia in hospitalized patients
• Identify life threatening causes of thrombocytopenia that require urgent intervention
• Formulate a differential diagnosis for thrombocytopenia using key clinical and laboratory parameters

Are Current Metrics Adequate to Demonstrate the Value of the Oncology AP?

• Differentiate between the concepts of productivity and value
• Identify the barriers to demonstrating the value of the oncology advanced practitioner (AP)
• Articulate metrics that would accurately demonstrate the value of an oncology AP

Armamentarium of Anemia Diagnoses: How to Make Sense of a Lack of Red Blood Cells

• Review a systematic approach to the differential diagnosis of anemia
• Interpret relevant laboratory tests used in the diagnosis of anemia
• Describe appropriate indications for treatments for anemia such as oral and IV iron, erythropoietin, and red blood cell transfusion

Biomarker Jeopardy

• Pair specific biomarkers with the tumor type(s) for which their expression is most commonly used to determine targeted therapy    
• Identify key assays used to measure common biomarkers
• Evaluate guideline-endorsed biomarker testing recommendations

Cardio-Oncology: The Intersection of Cardiovascular Disease and Cancer

• Identify patient risk factors common to both cancer and heart disease
• Explain how cardiovascular risk factors effect risk of cardiotoxicity associated with cancer therapy
• Describe the evolution and use of pharmacologic interventions available to mitigate and treat cancer therapy–related cardiotoxicities, such as statins, fenofibrate, ACE inhibitors, and beta-blockers
• Optimize approaches for mitigating and managing cancer therapy–related cardiotoxicity

Case Studies in AL and ATTR Amyloidosis

• Differentiate between AL and ATTR diagnoses   
• List key considerations when selecting the appropriate therapy
• Identify 3 ways the advanced practitioner can successfully manage supportive care needs of patients with AL and ATTR amyloidosis

Developments in Hepatocellular Cancer Treatment

• Review the diagnostic evaluation for hepatocellular cancer (HCC) in newly diagnosed patients at all stages of disease
• Discuss treatment options for the patient with HCC, including new systemic approaches
• Outline the advanced practice provider role in managing treatment-related adverse events with novel agents used in the management of HCC

FDA and its Role in Drug Development

• Discuss recent changes to the oncology drug development and approval process
• Describe the role of the AP in the execution of clinical trials
• Identify 3 changes that have taken place in the FDA's drug development and approval process as a result of the COVID-19 pandemic

Immune Checkpoint Inhibitors: Common Questions About Uncommon Adverse Events

• List special considerations for certain patient populations for initiating therapy and for patients undergoing rechallenge with immune checkpoint inhibitors
• Discuss recognition, monitoring, and management of rare and life-threatening immune-related adverse events (irAEs)
• Review strategies for managing irAEs in the corticosteroid-refractory setting 

Improving Outcomes in Hematopoietic Stem Cell Transplant: Recent Advances

• Identify GVHD treatments that improve stem cell transplant outcomes.
• Describe advances in management of infectious disease complications.
• Describe advances in post-transplant maintenance therapy.

Infrequent Offenders: Neuroendocrine Tumors and Cancers of the Appendix, Gallbladder, and Bile Duct

• Understand the presentation, diagnosis, and treatment of neuroendocrine tumors of the GI tract and appendix
• Understand the presentation, prognosis, and treatment of gallbladder cancer
• Differentiate the presentation of bile duct cancer based on the location in the bile duct
• Discuss the role of the advanced practitioner in the diagnosis and management of these infrequently seen malignancies

Keynote Interview: Words Matter: Use of Respectful Language in Oncology

• Identify and describe manifestations of implicit bias
• Develop an awareness of the power of words to convey respect and mitigate implicit bias among diverse populations
• Employ strategies to incorporate patient-centered and respectful language in your communication with the public, colleagues, and patients

Kidney Cancer: Tracking and Treating Symptoms With the Challenge of Combination Therapy

• Implement utilization of various guidelines to reduce side effect burden of combination cancer therapies.
• Discuss ways to partner with specialists from within or even outside your practice to gain knowledge and relationships to track and treat side effects of combination therapies.
• Apply strategies for teaching patients/families to track and report appropriate symptoms.

Management of Diabetes in the Patient With Cancer

• Recognize hyperglycemia and diabetes risk factors in the patient with cancer
• Review the importance of glycemic control in the cancer patient
• Become familiar with antihyperglycemic management principles and treatment in the patient with cancer
• Understand when to refer complicated patients who need intensive glycemic control management

Management of Progressive Chronic Lymphocytic Leukemia Beyond Ibrutinib

• Evaluate data on treatment advances and novel agents for managing relapsed chronic lymphocytic leukemia (CLL)
• Discuss the impact age and comorbidities have on treatment decisions for patients with CLL
• Compare and contrast the mechanism of action, indications, efficacy, depth and duration of clinical responses, and safety of current and emerging targeted agents for CLL

Mitigating the Morbidity of Financial Toxicity in Cancer Care

• Define "financial toxicity" in cancer care
• Identify risk factors and contributors to financial toxicity in cancer patients and their caregivers
• Describe the clinical and psychosocial consequences of financial toxicity
• Identify strategies to help cancer patients and families navigate the financial aspects of cancer care

New Drug Updates: Hematologic Malignancies

• Discuss the pharmacology and indications of the medications approved over the last 12 months for the management of patients with hematologic malignancies
• Review pivotal clinical trial data considered by the FDA when approving new oncologic agents and impact of these agents in advanced practice
• Identify the signs and symptoms of serious or life-threatening adverse effects of newly approved oncology medications

New Drug Updates: Solid Tumors

• Discuss the pharmacology, indications, and clinical trial data of oncology drugs approved for initial or expanded indications by the FDA over the past 12 months for the management of patients with solid tumors
• Identify the signs and symptoms of serious or life-threatening adverse effects of newly approved oncology drugs
• Describe the impact of these agents in advanced practice

Opening Panel: AP Leadership in Times of Crisis

• Discuss key elements of institutional emergency plans that must be in place to ensure the best outcomes possible during a potential crisis
• Describe how advanced practitioners (APs) were leveraged to care for patients during the COVID-19 pandemic
• Describe ways to assess and respond to the anxieties of AP colleagues and other staff members during a crisis

Sarcoma: Disease Overview and a Case-Based Approach to Treatment Updates

• Describe clinical features and diagnostic work-up of soft-tissue sarcoma (STS)
• Navigate the complexity of STS treatment plans
• Recognize this disease’s unique challenges, including the psychosocial needs of the sarcoma patient

Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer

• Determine which patients with cancer should be or could be treated with a direct oral anticoagulant (DOAC) and the factors involved in making benefit-to-risk decisions in unclear situations
• Describe the similarities and differences between DOACs, including the clinical data in patients with cancer
• Apply recent data evaluating the use of DOACs for the prevention and treatment of cancer-associated venous thromboembolism

The Elevator Pitch: Communicating Your Expertise, Experience, and Value to Patients, Co-Workers, and Prospective Employers in an Instant

• Define Elevator Pitch and its application to APs and healthcare
• Describe strategies for creating a personal brand
• Describe how characteristics of individuals can affect the delivery of your pitch
• Apply the knowledge of self and audience to deliver the perfect elevator pitch

The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

• Explain the current lung cancer treatment landscape
• Describe EGFR and Alk rearrangements and the updated treatment option landscape
• Compare the latest treatment options for BRAF, ROS1, NTRK, RET, MET, and KRAS
• Describe the different testing modalities for molecular markers